» Articles » PMID: 19367503

Cannabis Use Disorder: Epidemiology and Management

Overview
Publisher Informa Healthcare
Specialty Psychiatry
Date 2009 Apr 16
PMID 19367503
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

This paper provides an overview of the epidemiology of cannabis use, cannabis use disorders and its treatment. Cannabis is the most commonly used illicit drug internationally. While use is decreasing in the developed world, it appears to be stable or increasing in developing countries and some indigenous communities. Early initiation and regular adolescent use have been identified as particular risk factors for later problematic cannabis (and other drug) use, impaired mental health, delinquency, lower educational achievement, risky sexual behaviour and criminal offending in a range of studies. It is estimated that approximately one in ten people who had ever used cannabis will become dependent with risk increasing markedly with frequency of use. There has been an increase in the proportion of treatment provided for cannabis use. There are as yet no evidence-based pharmacotherapies available for the management of cannabis withdrawal and craving. Relatively brief cognitive behavioural therapy and contingency management have the strongest evidence of success, and structured, family-based interventions, provide potent treatment options for adolescents. With criminally involved young people and those with severe, persistent mental illness, longer and more intensive therapies provided by interdisciplinary teams may be required.

Citing Articles

Association of Cannabis Use Disorder With Hospitalizations for Pulmonary Embolism and Subsequent in-Hospital Mortality in Young Adults: A Contemporary Nationwide Analysis.

Desai R, Ghadge N, Kanagala S, Katukuri N, James A, Kadiyala A J Am Heart Assoc. 2024; 13(13):e032787.

PMID: 38934855 PMC: 11255712. DOI: 10.1161/JAHA.123.032787.


Cannabis Dependence is Associated with Reduced Hippocampal Subregion Volumes Independently of Sex: Findings from an ENIGMA Addiction Working Group Multi-Country Study.

Lorenzetti V, Gaillard A, McTavish E, Grace S, Rossetti M, Batalla A Cannabis Cannabinoid Res. 2024; 9(6):e1565-e1578.

PMID: 38498015 PMC: 11685300. DOI: 10.1089/can.2023.0204.


A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol.

Bhardwaj A, Mills L, Doyle M, Sahid A, Montebello M, Monds L BMC Psychiatry. 2024; 24(1):175.

PMID: 38433233 PMC: 10910760. DOI: 10.1186/s12888-024-05616-3.


Cannabis and tobacco use among adolescents aged 12-17 years from 16 low- and middle-income countries.

Wang Q, Wang H J Glob Health. 2023; 13:04066.

PMID: 37499128 PMC: 10374269. DOI: 10.7189/jogh.13.04066.


Old Dog, New Tricks: A Review of Identifying and Addressing Youth Cannabis Vaping in the Pediatric Clinical Setting.

Sharma P, Mathews D, Nguyen Q, Rossmann G, Patten C, Hammond C Clin Med Insights Pediatr. 2023; 17:11795565231162297.

PMID: 36993933 PMC: 10041590. DOI: 10.1177/11795565231162297.